Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Ovarian Neoplasms 2Malignant Ascites 2Ovarian High Grade Serous Adenocarcinoma 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1

Interventions

Paracentesis 2Bevacizumab 2regramostim 1recombinant human tumor necrosis factor-binding protein-1 1pembrolizumab 1molgramostim 1irinotecan sucrosofate 1Nivolumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Malignant Ascites × Paracentesis × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

NCT06266091 2025-07-20

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 2 Completed
115 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡